A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Prisma Health, Medical College of Wisconsin, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Emory University, Winship Cancer Institute, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Columbia University Irving Medical Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891233774